COVID-19

Learn more about PharPoint’s experience with COVID-19 clinical trials.

As the FDA continues to develop evolving guidelines, our industry has experienced a sudden, paradigm shift towards hybrid and virtual trials, with telemedicine becoming the “norm” for patient interaction across a variety of therapeutic areas.

As the situation with COVID-19 evolves, the PharPoint Research team is taking necessary precautions to ensure study operations continue uninterrupted. During this critical time in our industry, PharPoint remains fully dedicated, as always, to helping clients improve global health.